135 related articles for article (PubMed ID: 16794244)
1. Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.
Ramalingam S; Sandler AB
Oncologist; 2006 Jun; 11(6):655-65. PubMed ID: 16794244
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
3. Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Caponi S; Vasile E; Ginocchi L; Tibaldi C; Borghi F; D'Incecco A; Lucchesi M; Caparello C; Andreuccetti M; Falcone A
Clin Lung Cancer; 2010 Sep; 11(5):320-7. PubMed ID: 20837457
[TBL] [Abstract][Full Text] [Related]
4. Considerations for second-line therapy of non-small cell lung cancer.
Stinchcombe TE; Socinski MA
Oncologist; 2008; 13 Suppl 1():28-36. PubMed ID: 18263772
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
Ardizzoni A; Tiseo M
J Chemother; 2004 Nov; 16 Suppl 4():104-7. PubMed ID: 15688623
[TBL] [Abstract][Full Text] [Related]
6. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.
de Marinis F; Grossi F
Oncologist; 2008; 13 Suppl 1():14-20. PubMed ID: 18263770
[TBL] [Abstract][Full Text] [Related]
7. Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions.
Custodio A; de Castro J
Crit Rev Oncol Hematol; 2012 Jun; 82(3):338-60. PubMed ID: 21908201
[TBL] [Abstract][Full Text] [Related]
8. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
Ng R; Loreto M; Lee R; Leighl NB
Lung Cancer; 2008 Aug; 61(2):262-5. PubMed ID: 18358559
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
[TBL] [Abstract][Full Text] [Related]
10. Second-line treatment of advanced non-small cell lung cancer.
Gridelli C; Ardizzoni A; Ciardiello F; Hanna N; Heymach JV; Perrone F; Rosell R; Shepherd FA; Thatcher N; Vansteenkiste J; De Petris L; Di Maio M; De Marinis F
J Thorac Oncol; 2008 Apr; 3(4):430-40. PubMed ID: 18379366
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.
de Marinis F; Rossi A; Di Maio M; Ricciardi S; Gridelli C;
Lung Cancer; 2011 Jul; 73(1):1-10. PubMed ID: 21440325
[TBL] [Abstract][Full Text] [Related]
13. Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question.
Galetta D; Rossi A; Pisconti S; Millaku A; Colucci G
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S30-3. PubMed ID: 21129607
[TBL] [Abstract][Full Text] [Related]
14. Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies.
de Marinis F; De Santis S; De Petris L
Semin Oncol; 2006 Feb; 33(1 Suppl 1):S17-24. PubMed ID: 16472705
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
Li T; Ling YH; Goldman ID; Perez-Soler R
Clin Cancer Res; 2007 Jun; 13(11):3413-22. PubMed ID: 17545550
[TBL] [Abstract][Full Text] [Related]
16. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on salvage therapy for non-small-cell lung cancer.
Cappuzzo F; Finocchiaro G; Trisolini R; Toschi L; Bartolini S; Metro G; Crinò L
Oncology (Williston Park); 2005 Jul; 19(8):989-95; discussion 995-6, 999, 1003-4, passim. PubMed ID: 16131043
[TBL] [Abstract][Full Text] [Related]
18. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
[TBL] [Abstract][Full Text] [Related]
19. New avenues for second-line treatment of metastatic non-small-cell lung cancer.
Gridelli C; Maione P; Rossi A; Falanga M; Bareschino M; Schettino C; Colantuoni G; Guerriero C; Nicolella D; Rossi E; Ferrara ML; Palazzolo G
Expert Rev Anticancer Ther; 2009 Jan; 9(1):115-24. PubMed ID: 19105711
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
